Norway Savings Bank Sells 453 Shares of Johnson & Johnson (NYSE:JNJ)

Norway Savings Bank decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 16,656 shares of the company’s stock after selling 453 shares during the quarter. Johnson & Johnson accounts for about 1.5% of Norway Savings Bank’s holdings, making the stock its 21st biggest position. Norway Savings Bank’s holdings in Johnson & Johnson were worth $2,699,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $27,000. MFA Wealth Advisors LLC bought a new position in Johnson & Johnson in the second quarter valued at about $43,000. Grayhawk Investment Strategies Inc. lifted its holdings in shares of Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the last quarter. Fairfield Financial Advisors LTD acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $46,000. Finally, Fairway Wealth LLC increased its position in Johnson & Johnson by 217.1% during the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after purchasing an additional 228 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $174.31.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Up 1.4 %

Johnson & Johnson stock traded up $2.22 on Tuesday, hitting $163.82. 4,587,624 shares of the stock traded hands, compared to its average volume of 7,021,804. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The firm has a market cap of $394.26 billion, a P/E ratio of 10.07, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The business’s fifty day simple moving average is $162.60 and its 200 day simple moving average is $154.48. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.80 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.